Patient Adherence Higher With Enzalutamide Than Abiraterone in Advanced Prostate Cancer but Cognitive Screening Suggested

Findings from the ADHERE study to be presented during the 2022 ASCO Annual Meeting by Pasquale Rescigno, MD, PhD, of the Candiolo Cancer Institute, FPO-IRCCS, in Turin, Italy, indicate for the first time that patients with metastatic castration-resistant prostate cancer (mCRPC) aged ≥ 70 years who were prescribed enzalutamide were more likely to adhere to their prescribed treatment regimen than comparable patients who were prescribed abiraterone (Abstract 12044).